FDA downclassifies cell counters:
This article was originally published in Clinica
Executive Summary
Automated differential cell counters are being reclassified by the FDA from class III, high-risk, devices requiring premarket approval, to class II, medium-risk devices. Companies who want to market a device of this sort must consult the agency's special guidance on what is required in a premarket notification or 510(k) for the product, the agency said. The FDA first proposed reclassifying the devices in May 2001, based on the recommendations of its haematology and pathology devices advisory panel.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.